Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Other 4Thoracic 3Other solid neoplasm 3Lymphoid 3Tumor-Agnostic 2Other neoplasm 2Gynecologic 2Plasma cell 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Anxiety Disorders 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mindfulness-Based Stress Reduction × Dermatologic × Clear all
NCT03174808 2019-11-27

Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)

Yale University

Phase NA Terminated
3 enrolled
DermatologicLymphoid

Anxiety Disorders, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡